Pages

Friday, May 3, 2013

Unhealthy Prognosis for Venture-Backed Diagnostics



Tim Gallagher shared with you:
Some brilliant caution on molecular diagnostics from Bruce Booth. Turns out, MDx development is just about as risky and capital intensive as therapeutic development, with arguably less upside and liquidity.
 
Unhealthy Prognosis for Venture-Backed Diagnostics
forbes.com